B. Riley lowered the firm’s price target on Rigel Pharmaceuticals (RIGL) to $20 from $27 and keeps a Neutral rating on the shares after the company delivered updated data for R289 in lower-risk myelodysplastic syndrome. The firm says the lack of incremental eight-week responses reflects a weaker than expected efficacy signal, below its base-case scenario. While safety remains acceptable, the efficacy component reduces confidence at this stage, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals announces initial data from Phase 1b study of R289
- Rigel Pharmaceuticals price target raised to $27 from $17 at B. Riley
- Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA
- Biotech Alert: Searches spiking for these stocks today
- Rigel Pharmaceuticals price target raised to $23 from $15 at Piper Sandler